Dermata Therapeutics, Inc. (DRMA) Insider Trading & SEC Filings

Updated Jul 16, 2026 · Last SEC filing 2026-06-16

Dermata Therapeutics, Inc. (DRMA) has filed 1 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-06-16. 2 Form 8-K material event filings were reported by DRMA in the last 90 days. InsiderAlpha tracks every DRMA SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.

About Dermata Therapeutics, Inc. (DRMA)

SEC CIK	0001853816

90-Day SEC Filing Activity

Form 4 filings (90d)	1
Form 8-K filings (90d)	2
Latest Form 4 filing	2026-06-16

Recent DRMA Insider Transactions (Form 4)

Date	Insider	Role	Transaction	Shares	Price	Value	Filing
2026-06-16	Scott Kathleen D.	Director	S — Open-market sale	11	$1.19	$13	SEC
2026-02-17	Bedoya-Toro Munera Maria E	SVP, Regulatory Affairs	P — Open-market purchase	1.0K	$1.27	$1K	SEC
2025-12-23	PROEHL GERALD T	PRESIDENT, CHAIRMAN, CEO	A — Grant or award	490.2K	—	—	SEC
2025-12-23	PROEHL GERALD T	PRESIDENT, CHAIRMAN, CEO	A — Grant or award	122.5K	—	—	SEC
2025-12-23	Van Hoose Kyri K.	SVP, CFO	A — Grant or award	122.5K	—	—	SEC

All transactions sourced from SEC EDGAR Form 4 filings for Dermata Therapeutics, Inc. (DRMA). Updated in real time as new filings are submitted to the SEC.

Most-Active DRMA Insiders — Last 90 Days

Insider	Form 4 filings	Total transaction value
Scott Kathleen D.	1	$13

Recent DRMA Form 8-K Material Events

2026-05-27 — Item 5.02, 5.07, 9.01 [SEC]
2026-05-13 — Item 2.02, 9.01 [SEC]
2026-03-26 — Item 2.02, 9.01 · Earnings · neutral [SEC]
Dermata Therapeutics issued a press release on March 26, 2026, disclosing financial results for the fiscal year ended December 31, 2025, along with a corporate update. The filing provides standard annual financial results without indication of beat/miss or guidance changes.
2026-02-25 — Item 5.02 · Leadership · neutral [SEC]
Mary Fisher resigned from Dermata Therapeutics' Board of Directors effective March 31, 2026, due to her employer being acquired and no longer permitting board service. The resignation was not due to any disagreement with the company and will reduce board size from eight to seven

Recent Insider Filings

2026-06-16 — Scott Kathleen D. (Director)
2026-03-17 — Bedoya-Toro Munera Maria E (SVP, Regulatory Affairs)
2026-01-07 — PROEHL GERALD T (President, CEO and Chairman)
2026-01-07 — WIERENGA WENDELL (Director)
2026-01-07 — HALE DAVID F (Director)

Form 4 Transaction Code Reference

SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in DRMA insider filings:

P	Open-market purchase by the insider
S	Open-market sale by the insider
A	Grant, award, or other acquisition from the issuer
M	Exercise or conversion of derivative security (e.g. options)
F	Payment of exercise price or tax liability via share withholding
G	Bona-fide gift of securities
D	Disposition to the issuer (e.g. share buyback participation)
J	Other acquisition or disposition
X	Exercise of in-the-money or at-the-money derivative security
C	Conversion of derivative security
V	Transaction voluntarily reported earlier than required

DRMA Insider Trading — FAQ

What is the latest insider trade for DRMA?: Dermata Therapeutics, Inc. (DRMA) had 1 insider filings in the last 90 days, with the most recent on 2026-06-16. InsiderAlpha tracks every Form 4, 10-K, 10-Q, and 8-K filing in real time.
How many insiders are buying DRMA stock?: 0 insider purchases of DRMA were filed in the last 90 days.
How many insiders are selling DRMA stock?: 0 insider sales of DRMA were filed in the last 90 days.
Where can I see DRMA SEC filings (Form 4, 10-K, 10-Q, 8-K)?: InsiderAlpha aggregates every DRMA SEC filing — Form 4 insider transactions, 10-K and 10-Q quarterly reports, and 8-K material event disclosures — in one timeline.

Learn More

Open the live DRMA dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.